home / stock / vstm / vstm short
Short Information | Verastem Inc. (NASDAQ:VSTM)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 293,478 |
Total Actual Volume | 1,757,458 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 14,674 |
Average Short Percentage | 16.91% |
Is there a VSTM Short Squeeze or Breakout about to happen?
See the VSTM Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-03-2024 | $10.48 | $10.9 | $11.16 | $10.48 | 104,256 | 17,836 | 17.11% |
05-02-2024 | $10.01 | $10.36 | $10.45 | $9.81 | 78,935 | 10,807 | 13.69% |
05-01-2024 | $10 | $9.98 | $10.62 | $9.88 | 91,195 | 15,865 | 17.4% |
04-30-2024 | $9.67 | $9.98 | $9.99 | $9.67 | 83,804 | 12,542 | 14.97% |
04-29-2024 | $9.4 | $9.63 | $9.8 | $9.4 | 39,824 | 9,066 | 22.77% |
04-26-2024 | $9.23 | $9.38 | $9.52 | $9.23 | 42,669 | 8,484 | 19.88% |
04-25-2024 | $9.13 | $9.215 | $9.38 | $9.02 | 71,213 | 8,628 | 12.12% |
04-24-2024 | $9.54 | $9.31 | $9.75 | $9.27 | 78,623 | 13,553 | 17.24% |
04-23-2024 | $9.68 | $9.61 | $9.93 | $9.58 | 101,447 | 15,512 | 15.29% |
04-22-2024 | $9.84 | $9.74 | $10 | $9.671 | 95,499 | 16,616 | 17.4% |
04-19-2024 | $10.1 | $9.84 | $10.355 | $9.56 | 151,397 | 32,985 | 21.79% |
04-18-2024 | $10.89 | $10.23 | $11.02 | $10.19 | 66,842 | 15,901 | 23.79% |
04-17-2024 | $10.9 | $10.84 | $11.18 | $10.77 | 54,337 | 6,354 | 11.69% |
04-16-2024 | $11.03 | $10.93 | $11.49 | $10.93 | 64,334 | 10,663 | 16.57% |
04-15-2024 | $11.3 | $11.07 | $11.34 | $10.935 | 117,053 | 19,371 | 16.55% |
04-12-2024 | $11.76 | $11.3 | $11.77 | $11.1 | 85,312 | 13,978 | 16.38% |
04-11-2024 | $11.27 | $11.81 | $11.815 | $11.12 | 75,924 | 14,321 | 18.86% |
04-10-2024 | $11.5 | $11.3 | $11.66 | $11.12 | 92,040 | 18,828 | 20.46% |
04-09-2024 | $12.09 | $11.74 | $12.26 | $11.5988 | 124,297 | 12,327 | 9.92% |
04-08-2024 | $11.42 | $11.86 | $11.98 | $11.275 | 138,457 | 19,841 | 14.33% |
News, Short Squeeze, Breakout and More Instantly...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...